Why It Matters

Independence Blue Cross LLC, the Philadelphia-based regional health insurer, filed an amended lobbying disclosure filing for the second quarter of 2025, reporting $170,000 in in-house lobbying activity. The amendment arrives days after the company's director of financial investigations testified before Congress on Medicare fraud.

Independence Blue Cross operates at the intersection of nearly every major health policy debate now moving through Congress. ACA marketplace subsidies, Medicare Advantage payment rates, drug pricing, and site-neutral payment reform all carry direct financial consequences for the insurer and its roughly 3 million members.

By the Numbers

The $170,000 reported in this amended filing covers in-house lobbying only. It is one of several disclosures filed by Independence Blue Cross for the second quarter of 2025. Ballard Spahr LLP filed a separate second quarter report on the company's behalf, as did Salt Point Strategies LLC, which reported lobbying on the No Surprises Act implementation and health care payment policy. Cozen O'Connor Public Strategies LLC also filed a second quarter report, though it listed no specific issues.

The company's in-house lobbying team remains consistent. Jovi Hammer and Mitch Vidovich are the two lobbyists listed on this filing. Both bring congressional staff experience. Hammer served as a subcommittee director on the House Homeland Security Committee and previously as a professional staff member on the Senate Homeland Security and Governmental Affairs Committee. Vidovich served as regional director for southeastern Pennsylvania in the office of Sen. Patrick J. Toomey (R-PA).

Looking at the broader lobbying activity report across all registrants, Independence Blue Cross's in-house team has filed across multiple quarters going back to at least mid-2024. The in-house filings show $160,000 each for the second and third quarters of 2025, rising to $650,000 in the fourth quarter of 2025, before settling back to $190,000 in the first quarter of 2026. A separate set of amended filings signed April 29, 2026, covering the second quarter, third quarter, and fourth quarter of 2025, each report $170,000, $170,000, and $670,000 respectively, suggesting corrections or updates to previously reported figures.

There's one notable shift in the broader lobbying team. Salt Point Strategies LLC filed a termination in the first quarter of 2026, ending its registration for Independence Blue Cross. Around the same time, alb solutions registered as a new firm for the client, with lobbyists Veronica Jackson and Adam Buckalew, both of whom had previously lobbied for Independence Blue Cross through Salt Point Strategies. The transition reflects a firm change rather than a personnel change.

The Agenda

This particular amended filing lists no specific issues in the disclosure. However, the in-house team's other second quarter 2025 report provides a detailed picture of the agenda. According to that concurrent filing, Independence Blue Cross was lobbying on:

  • ACA individual market policy reforms
  • Medicare Advantage policy reforms
  • TRICARE competitive plan demonstration, with regional support from the delegation
  • Veterans health care, specifically new care coordination with the VA
  • Site neutral payment reform and enhanced oversight for hospital and provider billing practices
  • Rx drug pricing and pharmacy benefit manager reforms

By the first quarter of 2026, the in-house team's lobbying activity report shifted the ACA framing, referencing "ACA marketplace stability" and the "impacts from expiration of ACA enhanced premium tax credits," a more urgent formulation reflecting the approaching subsidy cliff.

Ballard Spahr's concurrent filings have consistently cited H.R. 1, the One Big Beautiful Bill Act, alongside Medicare Advantage, veterans care coordination, and the TRICARE pilot program, across the second quarter of 2025, third quarter of 2025, fourth quarter of 2025, and first quarter of 2026.

Broader Context

The timing of this amended filing is notable. Just eight days before it was signed, Independence Blue Cross's Director of Financial Investigations, Chris Deary, testified before the House Ways and Means Committee at a hearing on Medicare fraud. The April 21, 2026 hearing, titled "Protecting Patients and Taxpayers: Cracking Down on Medicare Fraud," featured Deary describing the company's fraud detection work and flagging structural barriers to data sharing.

"While payers like Independence Blue Cross have invested heavily in advanced analytics, provider monitoring, and clinical validation, we continue to face structural barriers, and data sharing remains constrained by regulatory and operational limitations that can slow the timely exchange of actionable information," Deary said, according to his hearing statement.

Two members of Congress noted the testimony publicly. Rep. Aaron Bean (R-FL) posted about questioning Independence Blue Cross's Director of Corporate and Financial Investigations on Medicare's "pay-and-chase" system. Rep. Brian K. Fitzpatrick (R-PA), whose district borders the insurer's home region, highlighted his exchange with Deary, connecting the hearing to his work on fraudulent opioid prescribing and addiction treatment scams.

The ACA subsidy question has drawn sustained congressional attention throughout the past year. Sen. Kirsten Gillibrand warned in September 2025 that without an extension, nearly 20 million Americans would face higher premiums. The enhanced premium tax credits ultimately expired at the end of 2025, and subsequent communications from members including Sen. Jeanne Shaheen have continued to press the issue into 2026.

The Bottom Line

Independence Blue Cross is a longstanding participant in federal lobbying, with a stable in-house team and a consistent roster of outside firms covering a wide range of health policy issues. The amended second quarter 2025 filing itself carries no issue detail, but the broader pattern of congressional lobbying records across multiple registrants fills in the picture. The company's agenda spans ACA subsidy policy, Medicare Advantage, veterans care, drug pricing, and fraud prevention, issues that are all active in Congress and directly tied to its core business.

Access the Legis1 platform for comprehensive political news, data, and insights.